Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
NCT04959474
Recruiting
This phase II trial studies the effect of calorie reduction while undergoing stereotactic ablative radiation therapy in treating patients with breast cancer. Stereotactic ablative radiation therapy (sABR) is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organ. Giving SABR before surgery may make the tumor smaller. Adding dietary restrictions in combination with radiation therapy may help increase l... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/30/2025
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage 2 Breast Cancer AJCC v8, Anatomic Stage 3 Breast Cancer AJCC v8, Breast Ductal Carcinoma in Situ, Invasive Breast Carcinoma, Triple Negative Breast Carcinoma
Register for Updates
Oral Aromatase Inhibitors Modify the Gut Microbiome
NCT05030038
Recruiting
The purpose of this research is to study the bacteria in participants' gut before receiving a medicine called an aromatase inhibitor for breast cancer and after participants receive medicine for breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Wake Forest Baptist Health Sciences, Winston-Salem, North Carolina
Conditions: Breast Cancer
Register for Updates
AlloSure Lung Assessment and Metagenomics Outcomes Study
NCT05050955
Recruiting
ALAMO is a prospective, multi-center, perspective, registry of patients receiving LungCare™ (AlloSure®-Lung, AlloMap Lung, and HistoMap) for surveillance post-transplant. This study aims to evaluate the diagnostic performance characteristics of AlloSure Lung (dd-cfDNA) to detect a spectrum of rejection (ACR, AMR) and allograft infection (Bacterial, Viral, Fungal, Mycobacterial, Parasitic).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Alabama (UAB), Birmingham, Alabama +21 locations
Conditions: Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
Register for Updates
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
NCT05118789
Recruiting
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of zidesamtinib (NVL-520), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors. Phase 1 will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of zidesamtinib in patients with advanced ROS1-positive solid tumors. Phase 2 will determine the objective... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/30/2025
Locations: UCI Medical Center, Orange, California +62 locations
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial
NCT05138575
Recruiting
This study will test whether pharmacologic agents that may improve mitochondrial function and energy fuel metabolism \[Empagliflozin (Empa)\], with and without additional supplements that increase perfusion and fatty acid oxidation \[Potassium Nitrate (KNO3)\], improve submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure with Preserved Ejection Fraction (HFpEF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Pennsylvania Health System, Philadelphia, Pennsylvania
Conditions: Heart Failure With Preserved Ejection Fraction
Register for Updates
MYTHS - MYocarditis THerapy With Steroids
NCT05150704
Recruiting
This is a phase III, multi-center international, single blind randomized controlled trial to test the efficacy of pulsed intravenous (IV) methylprednisolone versus standard therapy on top of maximal support in patients with Acute myocarditis (AM).
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
07/30/2025
Locations: University of California San Diego, San Diego, California +48 locations
Conditions: Myocarditis Acute
Register for Updates
MRI in High-Grade Glioma Patients Undergoing Chemoradiation
NCT05212272
Recruiting
The purpose of this research study is to see if investigators can predict how brain functioning changes after radiation treatment based on PET scans and blood tests. Most participants experience at least mild decreases in their memory or attention after radiation therapy. Investigators hope that PET scans, lumbar puncture, and blood tests might help investigators predict who might have larger changes in their brain function after radiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: High Grade Glioma
Register for Updates
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy
NCT05318027
Recruiting
Evaluate the feasibility of using a chatbot combined with continuous activity monitoring to proactively identify, appropriately triage and help manage patients' symptoms during cancer treatment Determine whether such an early outpatient clinic-based intervention can decrease rates of excess triage visits Correlate changes in activity and early symptom management to emergency department visits, unplanned inpatient hospitalizations and treatment breaks
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Lung Cancer, Gastrointestinal Cancer, Head and Neck Cancer
Register for Updates
Neoadjuvant Breast Cancer Time Restricted Eating
NCT05327608
Recruiting
A phase II study to evaluate an innovative approach of following time restricted eating (TRE) in patients with HER2- negative breast cancer who will start neoadjuvant chemotherapy (NCT) for a new diagnosis of stage I-III breast cancer. Participants at baseline will have a body mass index (BMI) of (25-40) and engage in a TRE 16:8 schedule which includes 16 hours of fasting and 8 hours of eating. Patients will continue TRE for 16 weeks while receiving NCT. For patients who report at the time of th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma in Situ, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Carcinoma
Register for Updates
Individualizing Corticosteroid Use in Pneumonia
NCT05334316
Recruiting
In this study, researchers propose a unique (individualized) approach to steroid treatment seeking to give the right dose of steroid to the right patient and at the right time. This study seeks to compare usual care to an individualized steroid dosing strategy by testing a marker of inflammation in the blood called C- reactive protein (CRP). The overall goal is to reduce an individual's exposure to steroids and the risk of potential side effects thereby increasing the potential benefit of using... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Pneumonia
Register for Updates
Short Term Sirolimus Treatment and MRI of the Brain and Lungs
NCT05386914
Recruiting
Alzheimer's disease is a devastating neurodegenerative disease characterized by accumulation of clumps (also called plaques) and bundles of fibers (also called tangles) in the brain, for which there is currently no cure. Sirolimus is an FDA-approved medication which may improve the blood flow to the brain. Part I: This study is designed to see if sirolimus treatment improves MRI blood flow to the brain in individuals with and without a genetic predisposition to Alzheimer's disease. Part I of th... Read More
Gender:
ALL
Ages:
Between 45 years and 65 years
Trial Updated:
07/30/2025
Locations: University of Missouri-Columbia, Columbia, Missouri
Conditions: Genetic Predisposition to Disease, Healthy Volunteers
Register for Updates
Reducing Tobacco Smoking: a Transcranial Direct Current Stimulation (TDCS) Telehealth Study
NCT05460676
Recruiting
The study aims to evaluate the feasibility of using Dorsolateral Prefrontal Cortex (DLPFC) Transcranial Direct Current Stimulation (tDCS) as a tool to decreasing distress and cigarette smoking. 46 participants currently smoking cigarettes, and seeking to decrease cigarette use will be recruited.
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
07/30/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Smoking Cessation
Register for Updates